Prion diseases are a group of infectious fatal neurodegenerative diseases. The conformational conversion of a cellular prion protein (PrP C ) into an abnormal misfolded isoform (PrP Sc ) is the key event in prion diseases pathology. Under normal conditions, the high-energy barrier separates PrP C from PrP Sc isoform. However, pathogenic mutations, modifications as well as some cofactors, such as glycosaminoglycans, nucleic acids, and lipids, could modulate the conformational conversion process. Understanding the mechanism of conformational conversion of prion protein is essential for the biomedical research and the treatment of prion diseases. Particularly, the characterization of cofactors interacting with prion protein might provide new diagnostic and therapeutic strategies.
Introduction
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a group of fatal diseases that affect the brain and nervous system of human and animals. Prion diseases of human include classic Creutzfeldt-Jakob disease (CJD), new variant CJD, Gerstmann-Sträussler-Scheinker syndrome (GSS), fatal familial insomnia, and kuru [1] . Prion diseases can present as sporadic, genetic, or infectious neurodegenerative disorders. Prusiner and other researchers [2] [3] [4] found prion that was proposed to denote a small proteinaceous infectious particle, which lacks genomic coding nucleic acids. Although not being accepted by all, protein-only hypothesis is supported by more and more experimental evidences. This hypothesis believes that the template-directed misfolding of prion protein (PrP) is the cause of prion diseases.
Normal cellular prion protein (PrP C ) is an N-linked glycoprotein located on the outer membranes via a glycophosphatidylinositol (GPI) anchor [ Fig. 1(A) ], widely expressed in various tissues and enriched in the central nervous system. Cellular prion protein is a soluble monomeric protein that is readily degradable by proteinase K. In contrast, scrapie prion protein (PrP Sc ) forms insoluble aggregates that show resistance to protease K digestion. Conformational conversion of a-helix-rich PrP C to misfolded b-sheet-rich PrP Sc , accounts for the development of prion diseases [5, 6] . The misfolding of prion protein is a protein-based replication process described as template assistance or nucleation polymerization models [7, 8] . In the template assistance model, PrP
Sc is supposed to be a stable monomer that binds with PrP C and induces the conformational conversion [7] . However, till now there is no experimental evidence for the existence of such a stable PrP Sc monomer. The nucleation polymerization is the most widely accepted model for the aggregation of prion protein and some other neurodegenerative diseases-related proteins [9] [10] [11] . According to the nucleation polymerization model (Fig. 2) , the nucleation step is rate-limiting for the formation of aggregation (lag phase). Once the nuclei are formed, the aggregates grow rapidly by the attachment of PrP monomers or oligomers (elongation phase). Moreover, it is generally recognized that fragmentation is a special and important feature of prion protein aggregation, which generates more active nuclei and could be toxic to neuronal cells [11] .
Thus far, three-dimensional structures of many mammalian PrP C have been resolved by solution nuclear magnetic resonance (NMR) or X-ray crystallography [12, 13] . And some studies also investigated the overall structure of PrP Sc [14] [15] [16] . However, the molecular mechanisms of this conformational conversion have not been completely elucidated. Since PrP C is a stable monomeric protein with low free energy, a high free energy barrier might prevent spontaneous conversion of PrP C into PrP Sc . Some cellular molecules such as glycosaminoglycans (GAGs), nucleic acids, and lipids have been identified as cofactors, which promote the prion protein conformational conversion [17] [18] [19] [20] .
In this review, we focus on the factors and their effects on the conformational conversion of prion protein in prion diseases. Specifically, we will discuss the pathogenic . Cofactors, such as GAGs, nucleic acids, or lipids are crucial for prion propagation by lowering the energy barrier through acting as catalysts for prion replication. The prion protein conformation conversion and aggregation is a complicated process. The cofactors might involve in all the procedures including initiation, nucleation, elongation, fibrils mature, and fragmentation.
Conformational conversion of prion protein mutations and modifications that influence the conformation of prion protein directly, as well as the cellular cofactors, which may modulate the prion protein misfolding through specific binding. These factors may also contribute to the infectious capability and strain-specificity of PrP Sc that have been discussed in other reviews [21] [22] [23] .
Pathogenic Mutations
Human familial prion diseases are associated with about 30 point mutations of the PRNP gene coding for the prion protein. As shown in Fig. 1(B) , most of the missense point mutations were located at the second and third a-helixes (a2 and a3 helixes) and the loop between them. Insertion or deletion mutations involve the N-terminal domain. Y145 stop codon and Q160 stop codon mutations result in the premature termination of PrP synthesis. These inherited mutations may facilitate the pathogenic process of prion diseases through various mechanisms.
First, point mutations influence the structural flexibility and stability by changing the salt bridge network existing among three a-helixes [24] . An in vitro study found that GSS-related H187R mutations resulted in a markedly decreased global thermodynamic stability of the prion protein and induced a spontaneous conversion to oligomeric b-sheet structure in the absence of denaturants [25] . Second, point mutations weaken the hydrophobic interactions between b2-a2 loop and C-terminal of a3 helix. CJD-related V210I and GSS-related Q212P mutants result in a structural disorder of the b2-a2 loop together with the increased distance between this loop and a3 helix, and lead to an exposure of hydrophobic residues to solvent [26, 27] . The point mutations close to the hydrophobic core of prion protein, such as V180I, F198S, V203I, and V210I, disturb the hydrophobic interaction and increase flexibility in parts of the structure [28] . Kinetic stopped-flow studies found that familial prion diseases-related mutations F198S, V180I, and V210I resulted in a significant increase of the population of the PrP folding intermediate, which was readily to form PrP Sc -like aggregates [29, 30] . Third, mutations might influence the interaction of prion protein with cellular cofactors. Shen and Ji [31] analyzed the prion diseases-related mutations and found that most of these mutations tend to enhance hydrophobicity or decrease negative and increase positive charge, which may strengthen the interaction between PrP and cofactors. The structure of CJD-related E200K from NMR is similar with wild-type PrP but may alter surface charges thus influence the electrostatic interactions with other cofactors [32] . PrP mutant with three additional octapeptide repeats at N-terminal was found to bind more GAGs [33] .
Studies at cellular level show that point mutations affect folding and maturation of PrP C in the secretory pathway of neuronal cells [34 -37] . The mutations within the hydrophobic domain G114V, A117V, and G131V showed an effect on translocation, resulting in slightly increased generation of a topological particular trans-membrane form [38] . Human PrP mutant D202N that is expressed in human neuroblastoma cells fails to fold into a mature conformation and accumulates in the endoplasmic reticulum as curly aggregates [39] . In all, diseases-related point mutations could be an important internal cause that influences prion protein misfolding. Different mutants may modulate PrP misfolding through different mechanisms, which show the different phenotypes of prion diseases.
Post-translational Modifications
Post-translational modifications always result in changes of protein size, charge, structure, or conformation leading to alterations of key biochemical characteristics such as protein hydrophobicity or binding affinity. Hyperphosphorylation and glycosylation of Tau protein are crucial to the molecular pathogenesis of neurofibrillary degeneration of Alzheimer's disease (AD) [40] , while phosphorylation and oxidation of a-synuclein significantly influence the pathology of Parkinson's disease [41] . Prion protein is a cell-surface protein that has two occupied N-glycosylation sites and a GPI anchor. PrP C and PrP Sc with oxidative modification were detected in patients suffering from prion diseases using mass spectrometry [42] . Phosphorylation of prion protein at Ser43 was found to induce the conformational change and aggregation in cells [43] . We next discuss posttranslational modifications and their effects on PrP misfolding.
Glycosylation modification
Mammalian PrP contains two consensus sites for N-linked glycosylation at asparagine residues 181 and 197 [ Fig. 1(C) ]. Previous studies found that a PrP C mutant with these two consensus sites was capable of converting PrP C into PrP Sc , which indicated that N-linked glycans were not essential for the conversion process [44] . Circular dichroism (CD) and 1 H-NMR spectroscopy studies showed that the three-dimensional structure of the natural glycosylated PrP and the bacteria expressed recombinant PrP were essentially identical [45] .
Some studies indicated that N-linked glycosylation protected the large regions of the prion protein surface from proteases and nonspecific protein-protein interactions, which inhibit the misfolding and amyloid formation [46] [47] [48] [49] . However, other researchers believed that glycosylation modification might modulate the efficiency of PrP Sc formation. And these post-translational modifications show strainspecific properties and contribute to the molecular basis of Conformational conversion of prion protein TSE strain variation [50] . Kim et al. [51] found that bacterially expressed PrP lacking the native GPI anchor was a poor substrate for PrP res amplification in a standard protein misfolding cyclic amplification (PMCA) reaction. GPI could anchor PrP C into the membranes and prevent some non-specific interactions which disturb the conformational changing [51] . In contrast, removal of N-linked glycosylation facilitated conversion into PrP res [52] . [52] . In addition, glycosylation modification also alters the overall conformation of misfolding products of prion proteins. Study using infrared spectroscopy indicated that different strains of PrP res molecules, which contained various GPI anchors and N-linked glycans, exhibited different b-sheet contents in secondary structure [53] . Electron and atomic force microscopy experiments also indicated that the protofilament ultrastructure of prion fibril was influenced by strain-dependent differences in glycosylation [54] .
Except N-glycosylation, PrP C contains many potential O-glycosylation sites. Recently, Ritchie et al. [55] identified the existence of lysine hydroxylation and O-glycosylation in CHO expressed recombinant PrP C . Molecular dynamics simulations showed that these modifications had a stabilizing effect on PrP b2-a2 loop. In addition, O-linked a-GalNAc at Ser-135 suppressed the amyloid fibril formation of the prion peptide 108-144, whereas the peptide with the same sugar at Ser-132 showed the opposite effect [56] .
To conclude, N-linked glycosylation modifications protect the native PrP C from misfolding, and GPI anchor is necessary for PrP C to locate on membrane. Meanwhile, glycans may influence the overall structure of PrP Sc that serves as a template of PrP C conformational conversion.
Oxidative modification
Compared with intrinsic glycosylation, oxidation is an abnormal modification of prion protein. Methionine, cysteine, tryptophan, tyrosine, and histidine residues are susceptible to oxidation, among which methionine is considered as one of the most reactive amino acids to be oxidized. Oxidation of methionine always has a drastic effect on protein structure and stability, because methionine sulfoxide (MetO) shows a much higher polarity and lower flexibility. During the course of prion diseases, accumulated reactive oxygen species can contribute to the oxidative damage of prion protein. Several studies have detected enhanced oxidative stress and an increase in the amounts of protein oxidation products in prion diseases-affected brains [57 -60] . In 1993, Stahl et al. [42] found that either one or two methionine residues (Met206 and/or Met213) were present in the form of MetO in PrP Sc . It has been shown that a large fraction of the methionine residues in brain PrP Sc are presented as MetOs [61, 62] . Human PrP E200K has been found spontaneously oxidized in humans suffering from familial CJD, which implicated that the oxidation of methionine residues represented an early and important event in the conformational conversion of PrP C [63] . In general, oxidative modification tends to decrease the stability of target proteins. Oxidative damage of UV lightexposed PrP was showed to induce the formation of unfolded intermediate states along an oligomerization pathway [64] . Redecke et al. [65] found 25 mers and 100 mers formed on the pathway of oxidative PrP aggregation in vitro. Other studies found that oxidation destabilized the native fold of PrP C and facilitated the transition to PrP Sc [66] [67] [68] . Studies using analogs of methionine residues or serine substitution mutations also indicated that deep oxidation of PrP enhanced the tendency to aggregation and misfolding [69, 70] . However, some experiments showed that the oxidization of PrP by H 2 O 2 drastically decreased the rate and efficiency of the conversion into PrP Sc -like amyloid fibrils [71] , due to early termination of elongation and interference with lateral assembly of protofilament into fibrils. As shown in Fig. 1(C) , among the nine methionine residues in PrP, Met205/206 and 213 are covered by nearby amino acids. Our unpublished studies indicated that the oxidation at Met205/206 and 213 promote the formation of toxic multimers of PrP.
Advanced glycation end-product modification Advanced glycation end-products (AGEs) are proteins that become glycated after exposure to reducing sugars, which react with amino groups of the proteins (Lys, Arg, N-termini) to form Schiff base adducts. Because the protein misfolding and deposit in vivo are always slow processes, it is not surprising that AGE adducts are present in many protein fibrils of degenerative diseases including prion diseases [72 -75] . AGE modifications of Tau, a-synuclein and b-microglobulin had been studied previously [76] [77] [78] and these results indicated that this kind of modification resulted in oligomerization and polymerization of amyloidogenic proteins. In 2002, Sasaki et al. [79] investigated the AGE modification in CJD patients and found the present of advanced glycation end products and the receptor for AGE in PrP Sc -positive plaques. Choi et al. [80] further reported that one or more lysines at residues 23, 24, and 27 of PrP Sc were covalently modified with AGEs. However, how these AGEs influence the conformational changing of PrP remains unclear.
Conformational conversion of prion protein

Cofactors
Because the onset of prion diseases always takes several years, many cofactors could involve in and play special roles in the pathology process. PMCA is an effective method to generate infectious PrP Sc in vitro [81] . In the classical PMCA procedure, brain homogenates that contain many brain-derived materials are indispensable in the amplification process [82] . With the sole addition of RNA and lipids, Wang et al. [83] reported the de novo generation of infectious prions in vitro by PMCA using exclusively recombinant PrP. Meanwhile, cofactors such as GAGs, nuclei acids, and lipids have been found to be the components of purified infectious PrP Sc [84] [85] [86] [87] [88] [89] . On the basis of these experiments, it could be concluded that these cofactors must play essential roles in the conformational conversion of PrP in prion diseases [20] .
Glycosaminoglycans
GAGs are long anionic polysaccharides formed of hyaluronate, chondroitin sulfate-A and chondroitin sulfate-C, dermatan sulfate, keratan sulfate, heparin sulfate, and heparin [90] . Previous researches examined brain section of TSE patient and found the presence of sulfated GAGs in PrP amyloid plaques, which had similar histochemical features to those found in AD [84, 85, 91] . Some experiments reported that sulfated glycans altered the cellular localization of PrP C and simulated endocytosis in culture cells [92] . Horonchik et al. [93] and Hijazi et al. [94] studied the relation between GAGs and PrP Sc infection and their results indicated that GAGs severed as a cellular receptor used both for prion uptake and for cell infection. Moreover, accumulation of PrP Sc also influences the metabolism of GAGs result in their accumulation and secretion in urine [95] .
The N-terminal of PrP C is compose of octarepeats containing several His residues, and these basic amino acids are found to be the key binding sites of negatively charged GAGs [96, 97] . Further studies identified three regions (residues 23-52, 53-93, and 110-128) of the prion protein capable of independent binding to heparin and heparan sulfate [98, 99] .
Generally speaking, heparan sulfate specifically binds to prion protein and thus increases the concentration of PrP in normal neuroblastoma cells [100] . The PrP conversion experiments under physiologically compatible cell-free conditions show that GAGs such as heparan sulfate and pentosan polysulfate stimulate PrP res formation. These GAGs can induce a loss of a-helical content in PrP C and may form a scaffold for PrP Sc construction [101, 102] . Taubner et al. [103] used NMR and CD spectrum to investigate the structural characteristics of the flexible N-terminal domain of prion protein bound with sulfated glycan. Their results showed that octarepeat region adopted a repeating loop-turn structure when bond with sulfated glycans. Furthermore, these bindings lead to the expose of hydrophobic surface that is crucial for oligomer assembly.
Nucleic acids
Although many researchers have pointed out that nucleic acid is not necessary for infection and propagation of prion diseases, it is really an important cofactor that is involved in the conformation changing process. There is no doubt that nuclei acid is one of the components of purified PrP Sc . Previous studies found the presence of small DNA oligonucleotides and polyadenylated RNA in highly purified scrapie prion preparations [86, 87, 104, 105] .
In 2006, Lima et al. [106] reported the low-resolution structure of PrP in complex with an 18-bp double-stranded DNA. On the basis of small-angle X-ray scattering and NMR spectroscopy, they found that both the N-terminal disordered region and globular domain of PrP were responsible for the binding with DNA [106] . DNA may play a special role in decreasing the activation barrier for the conversion from the a-helical into the b-sheet conformation. It modulates the misfolding of PrP through the binding with PrP and forming an aggregation intermediate [107] [108] [109] [110] . Synthetic prion fragment 106-126 was shown to have a specific interaction with DNA [111] and induced the polymerization and aggregation [112] . Using light scattering and ANS fluorescence techniques, Nandi and Leclerc [113] reported that recombinant PrP C could form amyloid-like aggregations in nucleic acid solutions.
Using PMCA method, Deleault et al. [114] reported that mammalian RNA preparations stimulated in vitro amplification of PrP res . Although RNA is not indispensable for the PrP Sc propagation, it may play a role in the pathogenesis of prion disease. The RNA interaction sites of PrP only locate on the N-terminal PrP domain, which is different from that of DNA [115] . RNA interacting with PrP was found to trigger the conformational conversion of ovine PrP and induce a decrease in a-helix content and an increase in b-sheet [116] . Gomes et al. [115] investigated the interaction of recombinant murine PrP with synthetic RNA sequences and with total RNA extracted from cultured neuroblastoma cells (N2a-RNA). Their results showed that PrP23-231 lost most of its secondary structure and immediately aggregated upon interaction with RNA. Furthermore, the PrP:N2a-RNA complex protected protein from proteinase K digestion [115] .
In all, both DNA and RNA can bind with prion protein and act as catalyst in the process of prion structural conversion instead of encoding genetic information.
Lipids
As mentioned above, native PrP
C is attached to extracellular surface by a GPI-anchor and enriched in lipid rafts [117] .
Conformational conversion of prion protein
Lovastatin-mediated depletion of cellular cholesterol of Hamster brain cells decreases the formation of PrP Sc [118] ; however, the sphingolipids depletion shows an opposite effect on PrP Sc generation [119] . These results suggested that cholesterol and sphingolipids play different roles in PrP metabolism [120] . Highly purified infectious prion rods were found to contain the sphingolipids at the molar ratio to PrP between 1:2 and 1:40 [88] , which suggested lipid was also a component of extracellular amyloid of PrP as other neurodegenerative disorders [89] .
PrP C can interact with acidic phosphatidylserine (POPS) but not phosphatidylcholine (POPC) via highly basic N-terminal part encompassing residues 23 -145 [121] . The binding of synthetic peptides representing fragments PrP23-89 and PrP23-110 was investigated using large unilamellar vesicles, and both peptides could bind with high affinity to lipids mixture containing the POPC and anionic head groups phosphatidylglycerol (POPG) or POPS at pH 5 but not at pH 7.4. Of note, the octapeptide repeat and either of the two polybasic regions (23-50 or 90-110) are needed for effective membrane interaction. NMR results indicated both peptides inserted deeply into the lipid bilayer with little membrane perturbation [122] . Critchley et al. [123] and Re et al. [124] further studied the interaction between PrP C and all three types of lipid membranes [single lipid membranes of negatively charged POPG or zwitterionic dipalmitoylphosphatidylcholine (DPPC), and mixed lipid raft membranes composed of DPPC/cholesterol/sphingomyelin], and found that this interaction was pH-dependent and particularly strong under acid conditions. The binding of PrP to all the three types of lipids is much stronger at pH 5 than at pH 7. These studies suggested that the ionic interactions appear to be the predominant driving force for the binding of PrP to acidic membranes while the hydrophobic interactions drive the association of PrP with zwitterionic lipids of the raft-like mixture. The highly conserved middle region of PrP was also involved in the PrPlipid interaction. The four Lys residues in the middle region are crucial in orienting the hydrophobic PrP-lipid contact. Both of the hydrophobic and electrostatic interactions contribute to this interaction [125, 126] .
The binding of PrP to zwitterionic gel-phase membranes of DPPC or raft-like lipid membranes composed of DPPC/ cholesterol/sphingomyelin leads to a higher content of a-helical structure [127] , which indicates that lipid-raft is helpful for stabilizing the conformation of PrP C [120] . In contrast, PrP interaction with negatively charged lipids could result in structural changes on PrP and induce the formation of amyloid fibrils or amorphous protein aggregations. The binding of PrP with the POPS or phospholipid vesicles (POPC/POPS micelles) results in a drastic reduction in the conformational stability of the folded C-terminal domain [121] . With heating treatment, full-length PrP in phospholipid bicelle solutions converted into a b-sheet-rich structure and further formed amyloid-like aggregates [128] . PrP106-126 was found to be capable to interact with lipid vesicles and showed a predominant b-sheet structure, which induced a liposome fusion and neurotoxicity [129] . Miura et al. [130] examined the effect of lipid membranes containing negatively charged ganglioside on the secondary structure of PrP106-126 and found that b-sheet formation is linked with self-association of the positively charged peptide on the lipids surface. Lipid monolayers deposited at the air/water interface induce rapid formation of highly ordered fibrils by PrP106-126, and the extent of fibrillation were dependent on the presence of negatively charged and unsaturated phospholipids in the monolayers [131] .
Metals
Metals including copper, manganese, iron, and zinc are all shown to play special roles in prion protein misfolding. Cu 2þ is the natural interacting divalent metal ion to PrP C [132] . It has been widely accepted that His60/68/76/84 in the octarepeat regions and His96/111 between the octarepeat regions and the globular C-terminal domain are the Cu 2þ -binding sites [133] [134] [135] . But the influence of Cu 2þ on the PrP misfolding is somewhat complicated. Some studies found that Cu 2þ induced a conformational change of long stored recombinant PrP C and incubation of brain extractions which contained PrP C with Cu 2þ generate proteinase K-resistant PrP [136, 137] . Our previous study showed that Cu 2þ could trigger structural conversion of PrP90-231 into b-sheet-rich neurotoxic soluble oligomers [138] . However, Bocharova et al. [139] demonstrated that Cu 2þ inhibited conversion of full length prion protein into amyloid fibrils at pH 7.2. Meanwhile, Cu 2þ can induce further aggregation of the amyloid fibrils into large clump through interfibrillar coordination of Cu 2þ by octarepeats [139] . Orem et al. [140] found that Cu 2þ but not Mn 2þ could inhibit the amplification of PrP res using PMCA reaction due to the structural stabilization effect. Fourier transform infrared analysis indicated that Cu 2þ binding changed the secondary structure and increased the hydrogen bonding within the N-terminal repeat peptide [141] . Results from the conformation recognizing antibodies also support this [142] . In addition, Cu 2þ binding to prion protein and subsequent structural changes have been found to be pH dependent [141] .
Previous studies of the trace element status in brains of patients with sporadic CJD showed a decrease of Cu 2þ and an increase in Mn 2þ of approximately 10 folds [143] [144] [145] . Although the binding affinity of Mn 2þ to PrP C is relatively lower compared with Cu 2þ , it does result in an increase of b-sheet content in prion protein conformation [146] [147] [148] .
Conformational conversion of prion protein
Furthermore, Mn 2þ could bind with Cu 2þ -saturated PrP via His96. This binding leads to a significant reduction of a-helix content and simulates PrP aggregation [147] . Mn 2þ -induced aggregation of PrP may be due to the association of preformed PrP oligomers to larger aggregates whereas Cu 2þ seems to inhibit this process [149] . Hesketh et al. [150] found that when exposed to Mn 2þ , PrP C can form oligomer seed and further induce the aggregation.
Singh et al. [151] reported that imbalance of iron homeostasis was a common feature of prion infected cells and animal models. PrP C was found to be involved in the cellular iron uptake and transport [152] . However, the binding site and the affinity of PrP C for iron remain unknown. Singh's group believe that the octapeptide repeat region of PrP C is not essential for iron binding, and the interaction of PrP C with iron depends on the conformation of PrP C rather than a specific amino acid sequence [153] . Till now, there is no direct evidence to prove that iron can influence the conformation of PrP C .
PrP
Sc aggregation may sequester associated iron and form a so-called 'redox-active nature' that is neurotoxic in prion diseases [153] .
Besides copper, manganese, iron, and zinc were also found to play special roles in prion diseases [154] . It has been shown that the binding of Zn 2þ and/or Cu 2þ can modulate the aggregation and neurotoxicity of a peptide 106-126 of human PrP [155] . Further studies are needed to elucidate the details of how Zn 2þ interacts with prion proteins.
Conclusion
Normally, PrP C always folds into a native structure with low free energy. According to classical thermodynamic and kinetic principles, large energy barrier prevents the conformational transition from PrP C to PrP Sc . Pathogenic mutations can decrease the energy barrier between PrP C and PrP Sc , and facilitate the conformational conversion directly by destabilizing the PrP C and accumulation of folding intermediate (Fig. 2) . Meanwhile, diseases-related point mutations could change the overall structure or induce an exposure of local part of prion proteins that facilitate the access of oxidant agent or the binding cofactors. Computational analysis predicted that pathogenic mutations increase the solvent exposure of Met206/213 and facilitate their oxidation [156, 157] . Our unpublished results also indicated that D178N mutant is more susceptible to oxidative damage compared with wild-type PrP. Human prion proteins with pathogenic mutations bind more GAGs, and GAGs promotes the aggregation of mutant PrP more efficiently [99] . The PrP mutant with insertion of additional three octapeptide repeats can also bind with more GAGs and are more susceptible to oxidative attack [33] .
Compared with mutations and modifications that influence the conformation of PrP C directly, cofactors tend to influence the conformational conversion through specific binding with PrP C . The interacting of cofactors could modulate the conformational conversion and decrease the free energy barrier between PrP C and PrP Sc by acting as an essential catalyst for prion replication, or as components to help to stabilize PrP Sc (Fig. 2) . It must be pointed out that these cofactors could not only influence the nucleation phase, but also have impact on the elongation and fragmentation of prion protein aggregation. GAGs and nucleic acids always act as scaffolds for the elongation of prion protein aggregates. Oxidative modification of prion protein was found to enhance the fragmentation of amyloid fibrils [71] . Lipids and RNA were shown to be involved in the maturation of prefibrils and lead to the extension of proteinase K digestion-resistance core of PrP fibrils [158] .
In addition, it is interesting to note that the binding of negatively charged cofactors with PrP accompanied with the competition with each other. Electrostatic interaction is regarded as the main driving force of prion protein interaction with polyanions. Highly basic unstructured N-terminal domain of prion protein is the common interaction site of GAGs, nucleic acids and lipids. Heparin was found to significantly interfere in membrane interactions of the PrP106-126 and inhibit lipid-induced fibrillation [159] . Similarly, low molecular weight heparin can form soluble complex with PrP in a pH-dependent way, and this binding can prevent RNA-induced aggregation [160] .
Understanding the molecular mechanism of conformational conversion and misfolding of prion protein is essential for the treatment and biomedical research of prion diseases. In this review, we summarized main experiments concerning the prion protein conformational change. On the basis of these findings, some conformation recognized antibodies have been designed [161] [162] [163] to be potential anti-prion molecules, which provide a passive immunotherapy for prion disorders. And other researches aimed to use synthetic nucleic acid aptamer as a competitive inhibitor to interfere the cofactors interacting with PrP [164, 165] . With the in-depth understanding of prion protein conformational changing, novel potential therapeutic approaches for prion diseases and other neurodegenerative diseases will be developed in the near future.
